NCT03695341已完成不适用
Fulvestrant Versus Everolimus Plus Exemestane for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitors: the Clinical Experience From Real -World
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 130
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI
详细描述
Fulvestrant versus Everolimus plus Exemestane for patients with Metastatic Breast Cancer resistant to Aromatase Inhibitors: the clinical experience from real -world
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with ER/PR+，HER2- Metastatic Breast Cancer
- •Patients who were refractory to previous Aromatase Inhibitors
- •Patients treated with Fulvestrant or Everolimus plus Exemestane in any line in metastatic setting in Fudan University Shanghai Cancer Center，starting from 2013.06.01-2016.06.01
- •Available medical history
排除标准
- •1.Incomplete medical history
结局指标
主要结局
PFS
时间窗: 6 weeks
Progression free survival
次要结局
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
500mg Fulvestrant Versus Exemestane in MBCBreast CancerNCT03575260Fudan University120
Unknown
3 期
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastLocally Advanced Malignant NeoplasmBreast CancerMetastatic Breast CancerNCT02404051Consorzio Oncotech745
尚未招募
不适用
It is a comparison between a combination of Bilastine with Montelukast and Fexofenadine with Montelukast in Allergic Rhinitis.CTRI/2022/11/047305ROHILKHAND MEDICAL COLLEGE AND HOSPITA
已完成
3 期
Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant PatientsOrgan Transplantation, Renal TransplantationNCT00154284Novartis114
终止
3 期
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast CancerBreast CancerNCT02137837SWOG Cancer Research Network37